Skip to main content
Skip to footer
Opens in a new tab
About
Our Philosophy
Meet Our Care Team
Your Care Experience
Services
Cancer Care
Laboratory Services
Same-Day CT Imaging
Liberty Pharmacy
Infusion Services
Clinical Trials
Is a Clinical Trial Right for Me?
Find a Clinical Trial
Frequently Asked Questions
About PhaseWell Research
Resources
Patient Resources
Patient Forms
Billing & Insurance
Educational Resources
Approved Oncology Drugs (PDF)
Referring Physicians
Contact Us
About
Our Philosophy
Meet Our Care Team
Your Care Experience
Services
Cancer Care
Laboratory Services
Same-Day CT Imaging
Liberty Pharmacy
Infusion Services
Clinical Trials
Is a Clinical Trial Right for Me?
Find a Clinical Trial
Frequently Asked Questions
About PhaseWell Research
Resources
Patient Resources
Patient Forms
Billing & Insurance
Educational Resources
Approved Oncology Drugs (PDF)
Referring Physicians
Contact Us
Category:
Myelofibrosis
A Phase 3, Randomized, Double-blind, Add-on Study of Navtemadlin plus Ruxolitinib vs Placebo plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis with Suboptimal Response to Ruxolitinib
September 11, 2026
An Open-Label, Multicenter, Phase 1b/2 Study of KRT-232 Combined with Ruxolitinib in Primary Myelofibrosis, Post-PV-MF, or Post-ET-MF with Suboptimal Response to Ruxolitinib
September 11, 2026
